Navigation Links
PURE Bioscience Schedules Second Quarter 2009 Financial Results Conference Call for March 12, 2009 at 1:30 P.M. PDT
Date:3/10/2009

SAN DIEGO, March 10 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE) today announced that Michael L. Krall, President and CEO, will host a conference call on Thursday, March 12th at 1:30 P.M. PDT to review and discuss second quarter 2009 financial results.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO)

Shareholders and other interested parties may participate in the conference call by dialing 877-407-8033 or (International) 201-689-8033 a few minutes before 1:30 P.M. PDT on March 12th, 2009.

The call is being webcast by Vcall and can be accessed at www.purebio.com. Investors can also access the webcast at www.InvestorCalendar.com.

The webcast will be available for replay through June 13th, 2009. A replay of the conference call will be accessible until May 13th, 2009 by dialing 877-660-6853 or (International) 201-612-7415 and entering the Account#: 286 and the Conference ID#: 316499.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

    PURE Investor Contact:
    Paul G. Henning, Vice President
    Cameron Associates
    (212) 554-5462
    paul@cameronassoc.com


'/>"/>
SOURCE PURE Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Greater Baltimore Committee to Announce Winners of 2009 Maryland Bioscience Awards at Ceremonies on March 12
2. Neurocrine Biosciences to Present at the Cowen and Company 29th Annual Health Care Conference
3. Seahorse Bioscience, Inc. Acquires BioProcessors Corp.
4. PURE Bioscience Board Appoints John J. Carbone, MD to Board of Directors
5. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
6. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
7. Pressure BioSciences, Inc. to Present at the EdgeWater Research Partners Spring 2009 Micro/Small-Cap Investor Conference
8. EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone
9. INVO Bioscience Completes Reverse Merger
10. Speid & Associates Partners With Genizon BioSciences to Reduce Attrition Rates of New Drug Compounds
11. Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... launch of the Supplyframe Design Lab . Located in Pasadena, Calif., the ... future of how hardware projects are designed, built and brought to market. , ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology:
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
Breaking Biology News(10 mins):